Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal reflux disease patients refractory to proton pump inhibitor therapy

Digestion

Volumn 86, Issue 4, 2013, Pages 315-322

  Kunsch, S ^a   Neesse, A ^a   Linhart, T ^a   Nell, C ^a   Gress, T M ^a   Ellenrieder, V ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bilitec; DGERD; GERD; Proton pump inhibitor

Indexed keywords

PANTOPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG MEGADOSE; DUODENOGASTROESOPHAGEAL REFLUX; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; MALE; MANOMETRY; PRIORITY JOURNAL; STOMACH FUNCTION DISORDER; STOMACH PH; TREATMENT DURATION; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; BILE REFLUX; DRUG RESISTANCE; ESOPHAGEAL PH MONITORING; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MANOMETRY; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; STATISTICS, NONPARAMETRIC;

EID: 84868262084     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000342234     Document Type: Article

References (31)

1. Tytgat GN, McColl K, Tack J, Holtmann G, Hunt RH, Malfertheiner P, Hungin AP, Batchelor HK: New algorithm for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 249-256.
2. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ: Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487-1493.
3. Charbel S, Khandwala F, Vaezi MF: The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100: 283-289.
4. Dent J, El-Serag HB, Wallander MA, Johansson S: Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2005; 54: 710-717.
5. Dekel R, Morse C, Fass R: The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 2004; 64: 277-295.
6. Coron E, Hatlebakk JG, Galmiche JP: Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol 2007; 23: 434-439.
7. Richter JE: The many manifestations of gastroesophageal reflux disease: Presentation, evaluation, and treatment. Gastroenterol Clin North Am 2007; 36: 577-5ix.
8. van PB, Numans ME, Bonis PA, Lau J: Shortterm treatment with proton pump inhibitors, H 2 -receptor antagonists and prokinetics for gastro-oesophageal reflux diseaselike symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004;CD002095.
9. Moayyedi P, Talley NJ: Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-2100.
10. Fass R, Mackel C, Sampliner RE: 24-hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment. J Clin Gastroenterol 1994; 19: 97-99.
11. Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005; 22: 79-94.
12. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669.
13. Tack J: The role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 24(suppl 2):10-16.
14. Vaezi MF, Lacamera RG, Richter JE: Validation studies of Bilitec 2000: An ambulatory duodenogastric reflux monitoring system. Am J Physiol 1994; 267:G1050-G1057.
15. Tack J, Koek G, Demedts I, Sifrim D, Janssens J: Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: Acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99: 981-988.
16. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J: Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-1402.
17. Gasiorowska A, Navarro-Rodriguez T, Wendel C, Krupinski E, Perry ZH, Koenig K, Moty B, Powers J, Fass R: Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104: 2005-2013.
18. Kunsch S, Linhart T, Fensterer H, Adler G, Gress TM, Ellenrieder V: Prevalence of a pathological DGER (duodeno-gastric-oesophageal reflux) in patients with clinical symptoms of reflux disease. Z Gastroenterol 2008; 46: 409-414.
19. Kunsch S, Neesse A, Linhart T, Steinkamp M, Fensterer H, Adler G, Gress TM, Ellenrieder V: Impact of pantoprazole on duodenogastro-esophageal reflux (DGER). Z Gastroenterol 2009; 47: 277-282.
20. Vaezi MF, Richter JE: Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 1995; 117: 699-704.
21. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J: Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52: 1397-1402.
22. Schweitzer EJ, Bass BL, Batzri S, Harmon JW: Bile acid accumulation by rabbit esophageal mucosa. Dig Dis Sci 1986; 31: 1105-1113.
23. Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, Harper E, Harrison R, Attwood SE, Jankowski JA: Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: Induction of c-myc by acidified bile acid in vitro. Gut 2003; 52: 174-180.
24. Zhang F, Altorki NK, Wu YC, Soslow RA, Subbaramaiah K, Dannenberg AJ: Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: Evidence for involvement of bile acids. Gastroenterology 2001; 121: 1391-1399.
25. Farre R, Fornari F, Blondeau K, Vieth M, De VR, Bisschops R, Mertens V, Pauwels A, Tack J, Sifrim D: Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 2010; 59: 164-169.
26. Castell DO, Vela M: Combined multichannel intraluminal impedance and pH-metry: An evolving technique to measure type and proximal extent of gastroesophageal reflux. Am J Med 2001; 111(suppl 8A):157SY159S.
27. Weigt J, Monkemuller K, Kolfenbach S, Malfertheiner P: Standards and innovations in the diagnosis of gastroesophageal reflux disease. Z Gastroenterol 2007; 45: 1141-1149.
28. Wise JL, Murray JA: Utilising multichannel intraluminal impedance for diagnosing GERD: A review. Dis Esophagus 2007; 20: 83-88.
29. Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, Mion F, Verin E, Galmiche JP, Sifrim D: Esophageal pH-impedance monitoring and symptom analysis in GERD: A study in patients off and on therapy. Am J Gastroenterol 2006; 101: 1956-1963.
30. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO: Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole. Gastroenterology 2001; 120: 1599-1606.
31. Pace F, Sangaletti O, Pallotta S, Molteni P, Porro GB: Biliary reflux and non-acid reflux are two distinct phenomena: A comparison between 24-hour multichannel intraesophageal impedance and bilirubin monitoring. Scand J Gastroenterol 2007; 42: 1031-1039.